Edwards Lifesciences Stock Drops 41% in Volume but Ranks 290th in Trading Amidst Positive Price Gains

On May 15, 2025, Edwards Lifesciences (EW) saw a trading volume of $346 million, marking a 41.22% decrease from the previous day. The stock ranked 290th in terms of trading volume for the day. Edwards Lifesciences' stock price increased by 0.17%, marking the fourth consecutive day of gains, with a total increase of 4.34% over the past four days.

Edwards Lifesciences' intra-annular transcatheter aortic valve replacement (TAVR) valves, specifically the Sapien 3 Ultra, have been compared to Abbott's Navitor TAVR valve in a recent study published in JACC: Cardiovascular Interventions. The study, which included nearly 4,000 patients, found that both valves had comparable clinical outcomes after one year. However, there were notable differences in procedural complications and hospitalization times. Patients treated with the Navitor valve had a longer mean hospitalization time and higher rates of new left bundle branch block and new permanent pacemaker implantation. The Sapien 3 Ultra valve, on the other hand, was associated with a higher early safety endpoint, including freedom from all-cause mortality, stroke, and major bleeding events.

The study also highlighted differences in echocardiographic findings. The Sapien 3 Ultra valve was linked to lower rates of paravalvular leak but higher residual transprosthetic gradients and a larger effective orifice area. These findings suggest that while both valves are effective, there are trade-offs in safety and function that warrant further investigation through dedicated randomized clinical trials.